Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

(2021) Erica L Mayer et al.   LANCET ONCOLOGY

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

(2021) T. Bachelot et al.   ANNALS OF ONCOLOGY

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

(2021) Sibylle Loibl et al.   JOURNAL OF CLINICAL ONCOLOGY

Early treatment-related neutropenia predicts response to palbociclib

(2020) Nicholas P. McAndrew et al.   BRITISH JOURNAL OF CANCER

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

(2020) Stephen R. D. Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma

(2019) E L Mayer et al.   ANNALS OF ONCOLOGY

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)

(2018) Kathy D. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

(2018) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00

(2016) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

(2016) Sunil Verma et al.   ONCOLOGIST

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer

(2012) N. Lynn Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

(2010) Dawn L. Hershman et al.   BREAST CANCER RESEARCH AND TREATMENT

Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients

(2010) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer

(2008) Ann H. Partridge et al.   JOURNAL OF CLINICAL ONCOLOGY